p53 protein is absent from the serum of patients with lung cancer. by Levesque, M. A. et al.
British Journal of Cancer (1996) 74, 1434-1440
©C) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
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Summary p53 protein, which accumulates intracellularly in over half of all human tumours, has also been
reported to be present in the sera of patients with various malignancies, including lung cancer. Using a
quantitative immunoassay, we measured p53 protein concentrations in 216 sera from 114 lung cancer patients
of whom 75 provided matched lung tumour tissues, which were also assayed for p53 protein. p53 protein levels
above the detection limit of 0.04 ng ml-' were detected in only two sera from lung cancer patients
(0.14 ng ml-1 and 0.27 ng ml-1), but not in any of 13 sera from non-malignant lung disease patients or in 100
sera from normal non-diseased individuals. The presence of these apparent traces of serum p53 protein
concentrations could not be related either to the p53 protein expression status of the primary lung tumours or
to the tumour stage, grade or histological type. By pretreating these two sera with anti-p53 antibody linked to
solid phase, and by the addition of mouse serum to neutralise possible heterophilic antibodies, the signals
arising from these sera were shown to be non-specific and possibly caused by heterophilic antibodies. We
conclude that our data do not support previous reports ofp53 protein in the sera of lung cancer patients. Since
immunoassays are subject to numerous sources of interference in serum, including heterophilic antibodies, we
suggest that the results of p53 protein analysis of serum specimens should be interpreted with caution.
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Wild-type p53 protein is a nuclear transcription factor with
multiple functions, including the induction of a GI/S cell
cycle checkpoint, DNA repair and programmed cell death,
following genomic damage (Kuerbitz et al., 1992; Lowe et al.,
1993; Smith et al., 1994). Deletion of one p53 allele, on the
short arm of chromosome 17, accompanied by the missense
point mutation of the other p53 allele is the most common
genetic feature of almost every human malignancy (Levine et
al., 1991; Hollstein et al., 1992), strongly suggesting that p53
inactivation plays a key role in tumorigenesis. Missense
mutation in most cases leads to the expression of a
conformationally altered, non-functional mutant p53 protein
which accumulates in the nucleus of affected cells and can be
demonstrated by immunochemical techniques. Levels of wild-
type p53 protein in normal cells, in contrast, are typically
undetectable. Of clinical relevance are reports of p53 genetic
abnormalities and the closely correlated p53 protein over-
expression, in neoplasms of breast (Thor et al., 1992), colon
(Remvikos et al., 1992), ovary (Levesque et al., 1995a) and
bladder (Esrig et al., 1994). Overexpression of mutant p53
may identify more aggressive tumours and hence patients
with unfavourable prognoses.
p53 mutation (Miller et al., 1992; Gazzeri et al., 1994;
Ryberg et al., 1994) and protein accumulation (Caamano et
al., 1991; Brambilla et al., 1993) also frequently occur in
primary lung carcinoma, which is the leading cause of cancer
mortality in North America (Boring et al., 1993). Prognosis
for these patients is largely dependent on the stage of the
tumour presenting at clinical diagnosis, although other
factors, including p53 overexpression in tumour tissue, have
also been reported to predict reduced patient survival
(Quinlan et al., 1992; Mitsudomi et al., 1993a). There is
strong evidence implicating the p53 gene as a target for
genotoxic agents in tobacco smoke (Suzuki et al., 1992;
Dosaka-Akita et al., 1994), supporting observations that p53
mutations are an early event in lung cancer progression
(Bennett et al., 1993; Walker et al., 1994). In addition to
immunohistochemistry, which has been extensively used in
clinical studies, enzyme-linked immunosorbent assay (ELISA)
methods have also been developed to detect both mutant and
wild-type p53 protein overexpression in tumour tissues
(Midgley et al., 1992; Vojtesek et al., 1992; Hassapoglidou
et al., 1993). The application of ELISA for the measurement
of p53 protein in lung neoplasms has recently been reported
(Pappot et al., 1996).
Whether tumour cells which overexpress p53 protein may
release it into the bloodstream has been the subject of only a
few investigations to date. A screen of 800 serum specimens
collected from patients with a wide range ofmalignancies was
unable to detect p53 protein in any specimen using an
immunofluorometric assay (Hassapoglidou et al., 1993). This
finding is consistent with those of other workers (Winter et
al., 1992) employing a commercially available p53 ELISA
method (Oncogene Science, Uniondale, NY, USA) on lung
cancer patient sera. More recently, however, elevated levels of
p53 protein have been reported in the sera of patients with
lung cancer (Luo et al., 1994; Braun et al., 1995) and colon
adenomas and carcinomas (Greco et al., 1994; Luo et al.,
1995), relative to the sera of control subjects, as well as in the
sera of patients with Hodgkin's disease (Trumper et al.,
1994), malignant lymphomas (Lehtinen et al., 1993;
Lahdeaho et al., 1994), breast cancer (Rosanelli et al.,
1993) and asbestosis with and without lung cancer
(Partanen et al., 1995). In all of these recent studies, p53
protein was quantified in sera by the same or similar ELISA
procedure. We report here the use of a recently developed
highly sensitive immunoassay of p53 protein (Levesque et al.,
1995b), which is suitable for all sample matrices including
serum. Because our initial inability to detect p53 protein in
the serum of cancer patients (Hassapoglidou et al., 1993) was
in conflict with the findings of other groups, we sought to
determine if the p53 immunoassay signals arising in serum
were truly p53-specific. This study, however, comparing p53
protein concentrations in sera and tumour tissue extracts of
patients with primary lung cancer, as well as reporting the
measurements of p53 protein levels in sera from non-
malignant lung disease patients and from normal indivi-
duals, suggests that p53 protein is not present in the sera of
patients with lung cancer.
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Cancer patients
Matched tumour and serum specimens were obtained from
75 patients who were operated on at St Joseph's Health
Centre in Toronto, Ontario, Canada between June 1993 and
August 1995 for resectable primary lung carcinoma. This
group consisted of 23 males and 52 females, and included 16
individuals less than 59 years of age, 32 between 60 and 69
years, 23 between 70 and 79 years, and four more than 80
years of age at the time of surgery. Only four patients lacked
a history of tobacco smoking. All but three patients were
staged at surgery according to the TNM classification system
(Beahrs et al., 1992): 46 were found to have stage I disease,
12 were in stage II, 12 had stage IIIA, one patient had stage
IIIB, and one patient had stage IV cancer.
Lung tumour specimens
All lung tumour specimens were obtained during routine
surgery for the treatment of primary lung cancer. This study
was approved by the ethics and research committee at St
Joseph's Health Centre, Toronto, Ontario, Canada. Immedi-
ately after surgery, a representative portion of each primary
lung tumour was selected during quick-section procedures in
the operating room, snap frozen and stored at -80°C for
subsequent p53 immunoassay (see below). Formalin-fixed,
paraffin-embedded sections of adjacent tumour tissue were
used routinely to establish the grade and histological type in
72 cases following World Health Organization guidelines
(WHO, 1982). Well-differentiated (GI) tumours were found
in six patients, 43 had moderately differentiated (G2)
tumours, 22 were poorly differentiated (G3) and one was
not differentiated (G4). Adenocarcinoma and squamous cell
carcinoma, represented by 32 and 34 cases, respectively,
accounted for the majority of specimens, while the remainder
consisted of carcinoid tumours (n = 3), small-cell carcinoma
(n =2), large-cell carcinoma (n = 2), and one each of
adenosquamous and carcinosarcoma histologies. Further
histological examination classified the tumour cellularity of
26 lung tumours as high (n = 10), intermediate (n = 12), or low
(n =4).
Approximately 200 mg of the frozen tumour tissue was
pulverised and subjected to cell lysis by incubation on ice for
30 min with 1 ml of a buffer containing 50 mM Tris, 150 mM
sodium chloride, 5 mM EDTA, 10 ml I` NP-40 surfactant,
10 mg I` phenylmethylsulphonylfluoride and 1 mg 1` each
of aprotinin and leupeptin. The soluble extracts were
obtained following centrifugation at 14 000 g for 30 min at
4°C and collection of the supernatant fractions. Extracts were
then assayed immediately for p53 protein as described below,
and for total protein content by the bicinchoninic acid (BCA)
method (Pierce Chemical, Rockford, IL, USA). In order to
determine the degree of heterogeneity for p53 protein
accumulation within individual tumour specimens, ten
tumour specimens were each further sampled at three
different surfaces, and the equivalent masses of tissue were
extracted and assayed for p53 protein. Normal lung tissue,
free of overt malignant infiltration, was cut from seven
surgical specimens at the margins of resection and
subsequently pulverised, extracted and assayed for both p53
protein and total protein as described above. These were
designated as control or 'normal' tissues.
Serum specimens
For each of the 75 lung cancer patients, preoperative and/or
post-operative aliquots of serum specimens were obtained
from the routine biochemistry laboratory. A preoperative
serum specimen was obtained from 54 patients: 17 on the
same day as surgery, 19 one day before and 18 two to nine
days before surgery. At least one post-operative serum was
obtained from 64 patients. Multiple post-operative samples
were collected from 12 patients up to 12 days after surgery:
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four patients provided two specimens, four patients had three
sera, and one patient each provided four, five, six and seven
specimens, respectively, after surgery. A preoperative serum
and at least one post-operative serum were collected from 43
patients. Sixty-eight sera were also obtained from 39 lung
cancer patients for whom no matched tumour tissues were
available. For these latter specimens, the dates of collection
relative to the date of surgery in each case were not known.
All sera were stored at -80°C until analysis.
Control sera from 100 individuals from the general
population without symptomatic disease were stored for no
longer than 6 months at -40°C. Further controls were
provided by 13 sera obtained from patients assessed at St
Joseph's Health Centre for non-malignant lung diseases,
including chronic obstructive lung disease (n = 5), pulmonary
embolism (n =2), sarcoidosis (n =2) or respiratory failure due
to other causes (n = 5). These specimens were frozen after
venipuncture and stored at -40°C before immunoassay.
p53 immunofluorometric assay
Lung tumour extracts and undiluted sera were assayed for
p53 protein in duplicate using a 'sandwich-type' immunoas-
say (Levesque et al., 1995b). Briefly, this method involves the
capture of soluble p53 by DO-1 monoclonal antibody
(Vojtesek et al., 1992) (gift from Dr David P Lane,
University of Dundee, Scotland) immobilised in microtitre
wells and probing with polyclonal CM-1 anti-p53 rabbit
antiserum (Midgley et al., 1992). Following addition of an
alkaline phosphatase-conjugated goat anti-rabbit secondary
antibody, detection of bound immunocomplexes was
achieved by addition of the substrate diflunisal phosphate;
the dephosphorylated product then enters into a complex
with terbium and EDTA emitting long-lasting fluorescence at
615 nm measured by a time-resolved fluorometer (Cyberfluor,
Toronto, Canada). Both mutant and wild-type p53 are
measured by this assay as DO-1 and CM-1 each recognise
both molecular forms of p53 (Midgley et al., 1992; Vojtesek
et al., 1992). Concentrations of p53 were interpolated from a
standard curve generated by the simultaneous assay of a
dilution series of an extract of Sf9 insect cells infected with a
baculoviral p53 expression vector (gift from Dr Thierry
Soussi, INSERM, Institut de Genetique Moleculaire, France)
as detailed elsewhere (Levesque et al., 1995b). Values of these
standards were established in turn by the assay of lyophilised
recombinant human p53 protein standards (Oncogene
Science, Uniondale, NY, USA) and extended from 0 to
75 ng ml-', containing the range of p53 concentrations
(-0.15-75 ng ml-') within which the assay response was
linear. The detection limit of the assay is approximately
0.04 ng ml-'. Interassay precision at a p53 protein concen-
tration equal to the first p53 protein standard (0.15 ng ml-1)
was calculated to be 15%. In lung tumour extracts, p53 levels
were expressed relative to the amount of total protein in the
cell lysates.
Serum specimens with p53 concentrations consistently
exceeding the detection limit on repeated analyses were
reassayed after incubation for 1 h at room temperature with
30% (v/v) DO-1 Sepharose (to immunoabsorb p53 protein),
anti-digoxin Sepharose (control) or uncoupled Sepharose
(control), used as 50% slurries, followed by centrifugation at
14 000 g for 30 min to collect the supernatants. The solid
phase Sepharose-antibody conjugates were prepared from
high titre ascites fluids collected from mice injected with
monoclonal DO-I or anti-digoxin-producing hybridomas
using standard procedures (Harlow and Lane, 1988), and
from CNBr-activated Sepharose 4B (Pharmacia, Uppsala,
Sweden) used according to the manufacturer's instructions. A
lung tumour extract prepared as above, and a serum
specimen from a hospitalised patient without evidence of
malignancy which was supplemented with 10% (v/v) lung
tumour extract, were also treated as above and then assayed
for p53 protein. Serum specimens containing detectable levels
of p53 protein were also tested for the presence ofSerum p53 protein in lung cancer
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heterophilic antibodies, a potential source of spurious
background signals in two-site immunoassays (Nahm and
Hoffmann, 1990). The fluorescence counts yielded by the
reassay of specimens 30 min after the addition of mouse
serum (50% v/v), with agitation at room temperature, were
compared with the counts elicited by assay of the same
specimens to which equivalent volumes of 6% bovine serum
albumin (BSA) (50 mM Tris, pH 7.80, 60 g 1-' BSA and
0.5 g 1-' sodium azide) had been added.
Results
All 75 lung tumour extracts had p53 protein concentrations
that exceeded the p53 detection limit of -0.04 ng ml-';
values ranged from 0.06 to 70.7 ng ml-' with a median p53
concentration of 0.52 ng ml-'. Because of variations in the
extraction efficiency, the levels of p53 protein were adjusted
for the total protein concentrations in the extracts. The
distribution of these adjusted p53 concentrations in the
tumour tissues was positively skewed (minimum, 8 ng g-';
maximum, 10 967 ng g-'; median, 133 ng g- ; mean,
1100 ng g-'; standard deviation, 2198 ng g-'). In order to
categorise tumour specimens as either p53-negative or p53-
positive, the median value of 133 ng per gram of total protein
was selected as the arbitrary cut-off point, shown in relation
to the histogram of the logarithmically transformed p53
values in Figure 1. Tumour tissues were roughly homo-
geneous for p53 protein overexpression, since three
independent extractions of tissue cut from different surfaces
of a small number of p53-positive (n=5) and p53-negative
(n = 5) specimens yielded p53 concentrations, adjusted for
total protein, which did not vary by more than 10% for each
tumour (data not shown). Normal lung tissue cut from the
resection margins of seven tumour-containing specimens
revealed much lower p53 concentrations which ranged from
10 ng g-' to 70 ng g-' with a median of 30 ng g-'.
Of all the sera collected from the lung cancer patients,
only two had p53 protein levels which consistently exceeded
the assay detection limit on repeated analyses, necessary for
the measurement of p53 protein levels in serum specimens
because of the random fluctuations of the assay at the
beginning of the calibration curve. One of these sera, having
a p53 protein concentration of 0.27 ng ml-1 (which exceeds
the first p53 protein standard in the linear portion of the
calibration curve) and denoted as patient serum 1, was
identified from a screen of 68 sera collected from patients
while they were in hospital for surgical removal of their
primary lung carcinomas. The other serum specimen,
henceforth referred to as patient serum 2, had a p53 protein
level of 0.14 ng ml-1 and was collected from a lung cancer
patient before surgery. Although it was known that this
patient had a poorly differentiated squamous cell carcinoma
which had invaded the visceral pleura but did not involve any
of the regional lymph nodes (stage I), correlation between the
appearance of detectable p53 protein in serum and any
clinicopathological feature was obviously not possible. The
relationship between p53 protein expression status by the
primary tumour and its detection in serum could similarly
not be addressed; the p53 protein concentration in the extract
prepared from this patient's lung tumour was 15 ng g-',
below the median cut-off point for p53 positivity. None of
the 100 sera from asymptomatic members of the general
population or the 13 sera from patients with lung diseases
other than malignancy had p53 protein concentrations
exceeding the assay detection limit.
To provide evidence that the fluorescence signals in
apparently 'p53-positive' sera were related to p53 protein
concentrations, patient sera 1 and 2 were further investigated
by a simple immunoabsorption procedure in which specimens
were incubated with Sepharose beads conjugated to DO-1
antibody to clear them of soluble p53 protein before assay.
The high capacity of DO-1 Sepharose to specifically
immunoabsorb p53 protein from a lung tumour extract is
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Figure 1 Frequency distribution ofp53 protein concentrations in
75 lung tumour tissues.
shown in Figure 2a; the assay of the tumour extract after
treatment with DO-1 Sepharose yielded only 8% of the
fluorescence counts generated by the assay of the same
extract after incubation with uncoupled Sepharose, used as a
dilution control since the conjugates were added as aqueous
slurries. The tumour extract, which had a p53 protein
concentration of approximately 10 ng ml-', was completely
cleared of detectable p53 protein as the signal after Sepharose
treatment did not exceed background. Treatment with
Sepharose, conjugated to an antibody against the irrelevant
antigen digoxin, resulted in a much smaller reduction of the
fluorescence signal. As shown in Figure 2b, DO-1 Sepharose
was also able to remove p53 protein from control sera which
was supplemented, to a p53 protein level of 0.8 ng ml-', with
p53-containing lung tumour extract. Again, background
fluorescence counts were achieved in these sera following
DO-1 Sepharose treatment. The high recoverability of p53
protein from serum (Levesque et al., 1995b) was confirmed by
the observation that dilution of the lung tumour extract 10-
fold by the control sera yielded fluorescence signals less than
seven times lower than that of the undiluted tumour extract
(data not shown). Given these results, the reduction in p53-
associated fluorescence after incubation of patient serum 1
with DO-1 Sepharose to 58% of the signal produced in the
same serum treated with uncoupled Sepharose (Figure 2c),
was suggestive that this serum specimen contained p53
protein. In contrast, no reduction in fluorescence counts
resulted from the treatment of patient serum 2 with DO-1
Sepharose (Figure 2d).
Because treatment of patient serum 1 with DO-1
Sepharose did not reduce the fluorescence signal to a
background level, as was the case when DO-1 Sepharose
was added to both the tumour extract-spiked control sera
and to the extract itself, we investigated the possibility that
the signals in these specimens were caused by the presence of
human antibodies with broad anti-species specificities which
might have cross-linked the solid phase DO-1, polyclonal
CM-1 or alkaline phosphatase-conjugated antibodies in our
immunoassay leading to false-positive results. A common
practice to neutralise these heterophilic antibodies, which
have been reported in the sera of up to 40% of normal
subjects (Boscato and Stuart, 1986), is the inclusion of non-
immune serum from a species used to raise one of the
analyte-specific antibodies to the sample assay buffer (Nahm
and Hoffmann, 1990). The large excess of mouse immuno-
globulins in mouse serum, added to human serum specimens,
would be expected to saturate the binding of any heterophilic
antibodies with anti-mouse specificity. Figure 2c shows that
when added to patient serum 1, mouse serum (added as 30%
of the total volume) was able to suppress completely the
fluorescence signal, unlike equivalent dilution of this serum
by the addition of immunoglobulin-free 6% BSA. The same
amount ofmouse serum added to patient serum 2 (Figure 2d)
or to either the tumour extract or the spiked control seraSerum p53 protein in lung cancer
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Figure 2 Treatment of specimens with solid phase conjugates (DO-1 Sepharose, anti-digoxin Sepharose and uncoupled Sepharose)
and testing for the presence of heterophilic antibodies. a, lung tumour extract (1Ongml-l p53 protein); b, normal control serum
spiked with lung tumour extract (0.8ngml- p53 protein); c, lung cancer patient serum I (0.27ngml-' p53 protein); d, lung cancer
patient serum 2 (0.14ngml-1 p53 protein). Controls in each case are uncoupled Sepharose (a and b) or uncoupled Sepharose and
mouse serum (c and d). See text for details.
(data not shown) were without similar effect. These results
strongly suggest that patient serum 1 contained non-specific
reactants with the sandwich immunoassay.
Discussion
Loss of p53 function is believed to impair a regulatory
pathway whereby DNA damage may trigger cell cycle arrest
or apoptosis in order to limit the propagation of harmful
mutations to daughter cells. The accumulation of mutations
leading to increased rates ofcell division, the ability to invade
locally and to metastasise, and the general escape from
cellular social controls governing cell behaviour provide the
molecular basis for neoplasia. Alterations to the p53 gene are
the most frequent genetic changes revealed so far in human
cancer and occur in 43-75% of non-small-cell lung cancers
(NSCLC)(Marchetti et al., 1993; Mitsudomi et al., 1993a;
Gazzeri et al., 1994) and 32-70% of small-cell lung cancers
(SCLC)(Miller et al., 1992; Lohmann et al., 1993; Ryberg et
al., 1994), demonstrating its importance in the pathogenesis
of these malignancies. Determination of the functional status
of p53 in cell lines, normal tissues and in tumours is most
often inferred by sequence analysis of p53 coding regions,
indirect methods of revealing the genotype, or by the
detection of p53 protein in the nuclei of tumour cells by
standard immunohistochemical techniques (Soussi et al.,
1994). Quantitative immunoassays for p53 protein, however,
may offer a number of advantages (Diamandis and Levesque,
1995) and have been applied to soluble cell extracts prepared
from breast (Bartkova et al., 1993; Vojtesek et al., 1993;
Levesque et al., 1995c), ovarian (Levesque et al., 1995a),
gastrointestinal (Bartek et al., 1991; Bartkova et al., 1993;
Joypaul et al., 1993), vulval (Bartkova et al., 1993), muscle
(Bartek et al., 1991), and more recently, in lung tumours
(Pappot et al., 1996). For tumours of three anatomic sites,
breast (Vojtesek et al., 1993), stomach (Joypaul et al., 1993)
and colon (Joypaul et al., 1993), parallel determinations of
p53 protein expression status by immunohistochemistry and
immunoassay have revealed that these methods yield
concordent findings.
Procedures less invasive than thoracotomy to remove
structures affected by lung cancer have also been shown to
indicate p53 mutational events directly or indirectly. Single
strand conformation polymorphism (SSCP) analysis of p53
exons 5 to 8 (Mitsudomi et al., 1993b), where the majority of
mutations occur in lung and other cancers (Hollstein et al.,
1991; Levine et al., 1991), and immunostaining for p53
protein (Bennett et al., 1993; Walker et al., 1994) in bronchial
biopsy specimens have demonstrated the potential for the
early diagnosis of lung cancer. In addition, sputum specimens
not cytologically diagnostic for cancer from patients who
later developed adenocarcinoma have been shown to contain
the same mutations identified in the primary lung lesion up to
a year before clinical diagnosis (Mao et al., 1994). Circulating
antibodies recognising p53 protein have been detected in the
sera of a proportion of both SCLC and NSCLC patients by
immunoblotting (Winter et al., 1992; Schlichtholz et al., 1994)
and by enzyme immunoassay (Angelopoulou et al., 1994;
Lubin et al., 1995). Patients expressing these antibodies have
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been shown to possess tumours harbouring p53 mutations
and to be highly positive for p53 protein (Winter et al., 1992).
Because the appearance of anti-p53 antibodies is likely to be
an early event in lung cancer (Lubin et al., 1995), and the
antibody titre may reflect the clinical course of the disease
(Angelopoulou et al., 1994; Lubin et al., 1995), measurement
of serum antibodies against p53 has been proposed for both
diagnosis and monitoring of lung cancer.
Attempts to detect in serum the p53 antigen which
elicited this antibody response were initially unsuccessful
(Winter et al., 1992; Hassapoglidou et al., 1993). A number
of subsequent studies however, have reported the presence of
p53 protein in serum. Over 30% of sera from patients with
malignant lymphomas were found to be positive for p53
protein in two Finnish studies correlating serum levels of
p53 with either thymidine kinase (Lehtinen et al., 1993) or
antibodies directed against the adenovirus 12 Elb protein
(Lahdeaho et al., 1994). A 64% p53-positivity rate in the
sera of Hodgkin's lymphoma patients was also reported
(Trumper et al., 1994). In another study, pre- and post-
operative serum specimens collected from 60 cases of
primary breast carcinoma and assayed for p53 protein
were found to exceed 1 ng ml-1 in five cases but did not
correlate with immunohistochemical p53-positivity in the
matched breast tumours (Rosanelli et al., 1993). Two groups
have provided evidence that serum p53 protein may be
measurable in patients with neoplasms of the colon. One of
these (Greco et al., 1994) has shown statistically significant
differences in median serum p53 values between patients
with colon adenoma (0.06 ng ml-') and adenocarcinoma
(0.10 ng ml-1), although, again, associations between serum
p53 and tumour stage, grade or site could not be
demonstrated. Another group (Luo et al., 1995) additionally
collected normal plasma controls, which were shown to
differ with respect to p53 concentrations from sera obtained
from patients with colon adenoma (mean, 0.44 ng ml-'),
with a 20% p53-positivity rate, and from patients with colon
carcinoma (mean, 0.55 ng ml-'), 32% of which were positive
for p53 protein. These same authors have also examined
serum levels of p53 protein in 23 cases of lung cancer, an
equal number of matched hospital controls, 58 members of
the general population and four people with non-malignant
lung disease (Luo et al., 1994). The mean p53 level in lung
cancer patients (0.55 ng ml-') was in fact higher than those
of non-malignant lung disease (0.42 ng ml-') or of the other
control subjects (approximately 0.32 ng ml-') for both
groups, but these differences did not achieve statistical
significance. Even more recent are reports of p53 protein
presence in the sera of patients with asbestosis, some of
whom also have lung cancer. While one group (Partanen et
al., 1995) was unable to find significant differences in mean
serum p53 protein levels between asbestosis patients with
(0.33 ng ml-') or without (0.29 ng ml-') cancer and control
subjects (0.61 ng ml-'), another group (Braun et al., 1995)
revealed that uranium miners with lung cancer had higher
serum concentrations of p53 (median, 0.23 ng ml-') than
those of control subjects, including smokers with lung cancer
(median, 0.06 ng ml-') and individuals without malignancy
(median, 0.03 ng ml-'), possibly signalling exposure to
radioactive radon. Unlike all of the above investigations,
which used commercial p53 ELISA methods, was a study
reporting levels of p53 protein in colon cancer patient sera
up to 106 ng ml-', determined by a chromatographic
procedure to extract tumour-associated antigens from sera
(Zusman et al., 1995). This latter finding deviates
tremendously from data obtained by ELISAs and should
be interpreted with caution.
In this report we have used a new immunoassay (Levesque
et al., 1995b) to measure p53 protein in both tumour tissue
and sera. Compared with our original assay configuration,
the new assay incorporated modifications, including the use
of microtitre plates coated directly with an anti-p53
monoclonal antibody, a detergent and mouse serum contain-
ing sample diluent, and a labelled secondary antibody diluent
containing goat serum, which greatly reduced the non-specific
background signals arising in many serum specimens from
hospitalised patients without cancer. Freedom from such
interference, the high recovery (range 72-131%, mean 90%)
of p53 protein from serum, and the generation of p53 results
concordant with the original method when applied to extracts
of non-diseased and malignant breast tissues, all indicated
that the new immunoassay was equally suited for the analysis
of p53 protein in both tissue extracts and serum specimens.
To our knowledge, only one other group (Pappot et al.,
1996) has used a quantitative ELISA-type method to detect
p53 protein in malignant lung tissue, rather than the more
widely used p53 immunostaining techniques. However, ours
is the first report of the use of an immunoassay for the
concomitant measurement of p53 protein in both tumours
and matched serum specimens. To classify tumour specimens
as either p53-negative or p53-positive, we used the median
p53 concentration of 133 ng g-' rather than the preferred
receiver operator characteristic analysis (Zweig and Camp-
bell, 1993), since a reference method for unequivocally
establishing p53 status has not been universally accepted.
This practice had also been adopted in work recently
reported (Pappot et al., 1996), in which a median p53
concentration of 100 ng g-' was found by the immunoassay
of 214 NSCLC extracts whose p53 values ranged from 0 to
700 ng g-'. The use of the median p53 concentration value
provides a more objective determination of p53 expression
status than the variety of immunohistochemical scoring
schemes used in other studies (Caamano et al., 1991;
Quinlan et al., 1992; Brambilla et al., 1993).
Given these findings by a number of groups of p53 protein
in the sera of patients with lung (Luo et al., 1994; Braun et
al., 1995; Partanan et al., 1995) and other (Lehtinen et al.,
1993; Greco et al., 1994; Lahdeaho et al., 1994; Luo et al.,
1994) malignancies, our failure to detect p53 in the sera from
over 100 lung cancer patients was surprising. In those
specimens in which p53 concentrations were found to exceed
the assay detection limit, subsequent reassay following either
immunoabsorption by solid phase anti-p53 antibody or
addition of immunoglobulins to neutralise possible cross-
linking heterophilic antibodies, provided strong evidence that
even these serum specimens were devoid of p53-specific
immunoreactivity. Confidence in our findings rests on several
attributes of our study design. Most importantly, for the
measurement of p53 protein concentrations we have used a
sensitive, well-characterised immunoassay (Levesque et al.,
1995b) yielding minimal background signals in serum, a
matrix recognised as containing numerous interfering
substances. We have also used this assay in conjunction
with further efforts to show the dependence of the signals in
serum on p53 protein. Finally, the collection of serum
specimens from 54 lung cancer patients immediately before
surgical removal of their tumours, all of which were also
characterised for p53 protein expression, afforded us the
greatest opportunity of detecting p53 in serum, assuming that
the primary tumour was the source of the circulating serum
protein. But as our results show, neither p53-positive nor
p53-negative tumour tissues were associated with detectable
serum p53 protein. Consequently, we could not determine if
p53 levels declined following surgery.
The most likely explanations for the discrepancy between
our findings and those of all others reporting p53 protein in
patient sera invoke potential differences between the
immunoassay methods used to quantitate serum p53
protein. The estimated analytical sensitivity of our method,
0.04 ng ml-', is superior to that of either the mutant p53
selective (0.25 ng ml-') or pantropic p53 (0.10 ng ml-1)
ELISA assays (Oncogene Science, Uniondale, NY, USA)
commonly employed in studies measuring p53 in serum.
Therefore, the relatively low p53 protein concentrations
reported in these studies would easily have been detected
by our immunoassay. Whether p53 protein is complexed by
serum components, masking its detection by the combination
of polyclonal CM-1 and monoclonal DO-1 immunoreagentsSerum p53 protein in lung cancer
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used in our assay yet allowing its detection by polyclonal
CM-1 and the monoclonal antibodies used in the other
assays, cannot be determined at present.
The potential of the measurement of p53 protein levels in
serum for the diagnosis and monitoring of a variety of
malignant conditions in which p53 is overexpressed is of
obvious clinical interest. The success of such an approach
might be limited, however, by three major biological
considerations: (1) not all tumour tissues, even those in
which the p53 gene has been mutated, show accumulation of
the p53 protein; (2) in many patients, the generation of
autoantibodies against p53 might mask epitopes of the
protein necessary for its detection by ELISA-type immu-
noassays; and (3) since p53 is a transcription factor thought
to function primarily in the nucleus and is not targeted for
extracellular release, it could probably enter the blood
circulation only by cell death within the tumour.
Investigators concerned with the measurement of p53
protein in biological fluids should also be aware of possible
analytical difficulties. p53 immunoassay designs which use
anti-species antibodies (e.g. an anti-serum raised in a goat
host against mouse IgG) to coat the solid phase are not
suitable for serum analysis since they are susceptible to non-
specific interference by heterophilic antibodies, which may be
present in up to 30% of normal individuals. These assays will
therefore yield false-positive results in a large proportion of
the patient sera tested. In addition, since all current ELISA-
type methods for p53 quantification include rabbit polyclonal
anti-p53 detection antibodies and subsequently added
enzyme-labelled anti-rabbit antibodies, it is imperative that
the anti-rabbit antibody used in each assay has been treated,
such as by adsorption to human IgG columns, in order to
eliminate any cross-reactivity with human IgG present in
serum specimens. Otherwise, in our experience, approxi-
mately 30% of human sera assayed will be apparently
positive for p53 protein. Once 'p53-positive' specimens are
identified, it is highly recommended to check for the presence
of heterophilic antibodies by treating the sera with mouse
IgG and then reassaying them. Since the ability to confirm
the molecular weight of the immunoreactive species in serum
by Western blotting is impaired by the relatively low
sensitivity of this procedure, other methods to demonstrate
the dependence of the assay response upon p53 protein, such
as the immunoabsorption experiment described here, are
required. Further indirect evidence for the existence of p53
protein in the sera ofcancer patients may also be provided by
the demonstration that p53 levels in the sera are compatible
with those found in the tumour tissues and that serum p53
concentrations decline following surgical removal of the
tumour. When all of these stringent criteria were applied,
none of the serum specimens assayed for p53 protein in this
study were found to have measurable p53 protein levels. The
presence of p53 protein in the sera of patients with lung
cancer is therefore not supported by the results of this study.
In the light of our finding, we strongly recommend that
before it is concluded that p53 protein is present in the sera
of patients with lung or other malignancies, stringent criteria
such as those outlined above should be used to identify p53-
specific assay responses. Immunological assays for p53
protein based only on monoclonal antibodies will probably
prove more successful for the assay of serum specimens but
as yet await development.
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